Compare LYFT & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYFT | TWST |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.2B |
| IPO Year | 2019 | 2018 |
| Metric | LYFT | TWST |
|---|---|---|
| Price | $15.65 | $90.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 8 |
| Target Price | $20.07 | ★ $46.88 |
| AVG Volume (30 Days) | ★ 12.8M | 2.2M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11250.00 | 63.89 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $6,316,261,000.00 | $376,572,000.00 |
| Revenue This Year | $17.33 | $18.91 |
| Revenue Next Year | $12.29 | $15.07 |
| P/E Ratio | $393.75 | ★ N/A |
| Revenue Growth | 9.16 | ★ 20.32 |
| 52 Week Low | $12.46 | $23.30 |
| 52 Week High | $25.54 | $105.47 |
| Indicator | LYFT | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 61.98 | 56.55 |
| Support Level | $12.85 | $42.88 |
| Resistance Level | $20.54 | $105.47 |
| Average True Range (ATR) | 0.67 | 6.98 |
| MACD | 0.12 | -1.42 |
| Stochastic Oscillator | 77.96 | 40.43 |
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.